Elevation Oncology Inc

Elevation Oncology — Corporate Update (July 2022)

16 slides from Elevation Oncology's corporate update, Jul 28, 2022

  1. Slide 1: Expanding Pipeline with EO-3021 Investor Conference Call

    Expanding Pipeline with EO - 3021 Investor Conference Call JULY 28, 2022

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements These slides contain forward - looking statements and information relating to Elevation Oncology, Inc. within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on f

  3. Slide 3: Today's Agenda

    Overview of the Deal Role of Claudin18.2 in Cancer Opportunity for EO - 3021 Closing Remarks 3 Today’s Agenda Shawn M. Leland, PharmD RPh FOUNDER AND CHIEF EXECUTIVE OFFICER David Dornan, PhD CHIEF SCIENTIFIC OFFICER Valerie M. Jansen, MD PhD CHIEF MEDICAL OFFICER Shawn M. Leland, PharmD RPh FOUNDER

  4. Slide 4: Overview of the Deal

    4 Shawn M. Leland , PharmD RPh OVERVIEW OF THE DEAL FOUNDER AND CHIEF EXECUTIVE OFFICER

  5. Slide 5: Building a Leading Precision Oncology Pipeline

    5 Building a Leading Precision Oncology Pipeline Strategy for Pipeline Expansion 1 The CRESTONE study is designed as a potential registrational trial following an accelerated approval pathway contingent upon con tinued discussions with the FDA 2 Report additional clinical data from Cohort 1 of the C

  6. Slide 6: Expanding Pipeline with a Differentiated ADC Candidate Targeting Claudin18.2

    6 EO - 3021 Expanding Pipeline with a Differentiated ADC Candidate Targeting an Attractive Market Opportunity in Claudin18.2 Claudin18.2 expressed across several solid tumor types including many GI cancers Clinically validated oncology target Potential for EO - 3021 to play a transformative role in

  7. Slide 7: Role of Claudin18.2 in Cancer

    7 David Dornan, PhD ROLE OF CLAUDIN18.2 IN CANCER CHIEF SCIENTIFIC OFFICER

  8. Slide 8: Claudin18.2 is a Unique and Highly Selective Target

    Claudin18.2 is a Unique and Highly Selective Target 8 ● Claudin18.2 is a highly selective cell surface target often overexpressed in several types of cancers ● Claudin18.2 is largely inaccessible to antibodies in normal tissue, but is exposed on epithelial surface during tumorigenesis ● Overexpresse

  9. Slide 9: A Differentiated ADC Targeting Claudin18.2

    EO - 3021 – A Differentiated ADC Targeting Claudin18.2 9 Linker Anti - Claudin18.2 Antibody MMAE Payload

  10. Slide 10: Opportunity for EO-3021

    10 Valerie M. Jansen, MD PhD OPPORTUNITY FOR EO - 3021 CHIEF MEDICAL OFFICER

  11. Slide 11: Significant Global Opportunity for Patients with Tumors Expressing Claudin18.2

    ● O verexpressed in several high unmet need cancers, including gastric, esophageal, pancreatic, ovarian, and NSCLC, among others ● Expression is highest in GC/GEJ and pancreatic tumors (≥70%) ● Elevation Oncology’s license to EO - 3021 is for all global territories outside Greater China Significant

  12. Slide 12: Expected to Enter US Clinical Trials in 2023

    12 EO - 3021 Expected to Enter US Clinical Trials in 2023 Ongoing Phase 1 dose - escalation and dose - expansion study of EO - 3021 (SYSA1801) being conducted in China by CSPC IND cleared for EO - 3021 in US US Phase 1 clinical trial of EO - 3021 expected to be initiated by Elevation Oncology in 202

  13. Slide 13: Closing Remarks

    13 Shawn M. Leland , PharmD RPh CLOSING REMARKS FOUNDER AND CHIEF EXECUTIVE OFFICER

  14. Slide 14: Building an Industry-Leading Precision Oncology Company

    14 Obtained exclusive worldwide rights (outside Greater China) to develop and commercialize EO - 3021 EO - 3021 is a potential first - in - class, best - in - class, clinical - stage ADC targeting Claudin18.2 and currently in Phase 1 dose - escalation trial in China Claudin18.2 is clinically validat

  15. Slide 15: Key Upcoming Milestones

    15 KEY UPCOMING MILESTONES *As of March 31, 2022 ~$132.1M cash and cash equivalents* Cash runway into 2024 Mid - 2022 Report initial data from CRESTONE Cohort 1 SERIBANTUMAB First Half 2023 Report additional interim data from CRESTONE Cohort 1 Mid - 2022 Complete enrollment of the first 20 patients

  16. Slide 16: Q&A

    Q&A Shawn M. Leland, PharmD RPh Founder and CEO David Dornan, PhD Chief Scientific Officer Valerie M. Jansen, MD PhD Chief Medical Officer Joseph Ferra Chief Financial Officer

Elevation Oncology — Corporate Update (July 2022) on 6ix